Mesoblast stem cell therapy advances into Phase II for spinal degeneration
This article was originally published in Scrip
Executive Summary
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.